The tRNA-Derived Fragment tRF-E Promotes Ferroptosis in Hepatocellular Carcinoma to Suppress Tumor Progression.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. tRNA-derived fragments (tRFs) have been shown to play various roles in HCC tumorigenesis. In the current study, we identified that tRF-Glu-i-0545 (tRF-E), which is derived from an internal region of tRNA-Glu, is a tumor suppressor in HCC. tRF-E was significantly downregulated in HCC samples, and low tRF-E levels were associated with poor prognosis of HCC patients from multiple cohorts. tRF-E sensitized HCC cells to ferroptosis in vitro and in vivo. Mechanistically, tRF-E interrupted binding of VDAC2 to the E3 ligase Nedd4 to block ubiquitination and promote VDAC2 stabilization, which enhanced iron-dependent lipid peroxidation and ultimately triggered ferroptosis. The RNA binding protein SRSF6 cleaved tRNAGluTTC to generate tRF-E, and hypoxia inhibited tRF-E biogenesis by suppressing SRSF6. Specifically, hypoxia-induced alternative splicing of SRSF6 mRNA produced a long transcript containing a poison cassette exon, which led to nonsense-mediated mRNA decay. In conclusion, this study identifies a tumor suppressive tRF that enhances ferroptosis sensitivity in HCC and illustrates the potential of tRFs in cancer treatment.